GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities.

We are developing our late-stage product candidate, voxelotor (GBT440), as an oral, once-daily therapy for sickle cell disease, or SCD. Our pivotal program called the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study is currently underway.